Tiffany Troso-Sandoval, MD

Board-Certified Medical Oncologist | Breast and Gynecologic Cancers
drtiffanytroso@winningthecancerjourney.com | drtiffanytroso.com

EDUCATION

BA, Molecular Biology 1987 - 1991
Princeton University, Princeton, NJ

MD, Doctor of Medicine 1992 - 1996
Weill Medical College of Cornell University, New York, NY

POSTDOCTORAL TRAINING

Internship and Residency, Internal Medicine 1996 - 1999
New York Hospital / Cornell University, New York, NY

Fellowship, Medical Oncology 1999 - 2001
Memorial Sloan Kettering Cancer Center, New York, NY

BOARD CERTIFICATION

American Board of Internal Medicine: Internal Medicine 1996 - 2019

American Board of Internal Medicine: Medical Oncology 2001 - present

PROFESSIONAL CLINICAL EXPERIENCE

Assistant Attending Physician 2001 - 2013
Memorial Hospital for Cancer & Allied Diseases, Rockville Centre, NY

Associate Attending Physician 2013 - 2019
Memorial Hospital for Cancer & Allied Diseases, Rockville Centre, NY

Associate Attending Physician, Gynecological Medical Oncology 2019 - 2024
Memorial Sloan Kettering Cancer Center at Nassau, Uniondale, NY

OTHER PROFESSIONAL EXPERIENCE

CEO and Founder, Winning The Cancer Journey, LLC
Education, support, and guidance for female oncology patients through online courses, coaching, and group support.

Chief Medical Officer, Second Look Oncology, PLLC
Private virtual oncology consultations that help women with breast and gynecologic cancers understand their diagnosis, treatment plan, and options, and prepare for decisions with their treating oncology teams.

Expert Speaker and Consultant, Hologic / Biotheranostics2020 - 2025. *The Breast Cancer Index.*

Consultant and Advisory Board, Immunogen / AbbVie2022 - 2025

Medical Consultant 2021-present. CNN, Fox News, CH12, Women's Health,

PROFESSIONAL MEMBERSHIPS

American Society of Clinical Oncology (ASCO) 2001 - present

Society of Gynecological Oncologists 2015 - present

Society for Integrative Oncology 2016 - present

Institute for Functional Medicine 2024 - present

PUBLICATIONS

Peer-Reviewed Journal Articles

1. Friedman CF, Manning-Geist BL, Zhou Q, Soumerai T, Holland A, Da Cruz Paula A, Green H, Ozsoy MA, Iasonos A, Hollmann T, Leitao MM Jr, Mueller JJ, Makker V, Tew WP, O'Cearbhaill RE, Liu YL, Rubinstein MM, Troso-Sandoval T, Lichtman SM, Schram A, Kyi C, Grisham RN, Causa Andrieu P, Wherry EJ, Aghajanian C, Weigelt B, Hensley ML, Zamarin D. "Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses." Nature Medicine. 2024 May;30(5):1330-1338.
2. Lumish M, Chui MH, Zhou Q, Iasonos A, Sarasohn D, Cohen S, Friedman C, Grisham R, Konner J, Kyi C, Rubinstein M, Troso-Sandoval T, Aghajanian C, Makker V. "A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma." Gynecol Oncol. 2024.
3. Shen S, Ma W, Brown D, Da Cruz Paula A, Zhou Q, Iasonos A, Tessier-Cloutier B, Ross DS, Troso-Sandoval T, Reis-Filho JS, Abu-Rustum N, Zhang Y, Ellenson LH, Weigelt B, Makker V, Chui MH. "HER2 genetic intratumor heterogeneity is associated with resistance to trastuzumab and trastuzumab emtansine therapy in recurrent high-grade endometrial cancer." Mod Pathol. 2023.
4. Praiss AM, Zhou Q, Iasonos A, Moukarzel L, Dessources K, Soldan K, Su K, Sonoda Y, Roche KL, Gardner GJ, Troso-Sandoval T, Tew WP, Grisham RN, Chi DS, O'Cearbhaill RE, Zivanovic O. "Morbidity after secondary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for ovarian cancer." Gynecol Oncol. 2023.
5. Rubinstein MM, Doria ER, Konner J, Lichtman S, Zhou Q, Iasonos A, Sarasohn D, Troso-Sandoval T, Friedman C, O'Cearbhaill R, Cadoo K, Kyi C, Cohen S, Soldan K, Billinson E, Caird I, Jang D, Eid K, Shah P, Guillen J, Aghajanian C, Zamarin D, Makker V. "Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma." Gynecol Oncol. 2023.
6. Walsh EM, Gucalp A, Patil S, Edelweiss M, Ross DS, Razavi P, Modi S, Iyengar NM, Sanford R, Troso-Sandoval T, Gorsky M, Bromberg J, Drullinsky P, Lake D, Wong S, DeFusco PA, Lamparella N, Gupta R, Tabassum T, Boyle LA, Arumov A, Traina TA. "Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple-negative breast cancer: a feasibility study." Breast Cancer Res Treat. 2022.
7. Moore KN, Chambers SK, Hamilton EP, Chen LM, Oza AM, Ghamande SA, Konecny GE, Plaxe SC, Spitz DL, Geenen JJJ, Troso-Sandoval TA, Cragun JM, Rodrigo Imedio E, Kumar S, Mugundu GM, Lai Z, Chmielecki J, Jones SF, Spigel DR, Cadoo KA. "Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer." Clin Cancer Res. 2022.
8. Zivanovic O, Chi DS, Zhou Q, Iasonos A, Konner JA, Makker V, Grisham RN, Brown AK, Nerenstone S, Diaz JP, Schroeder ED, Langstraat CL, Paroder V, Lakhman Y, Soldan K, Su K, Gardner GJ, Andikyan V, Guo J, Jewell EL, Long Roche K, Troso-Sandoval T, Lichtman SM, Moukarzel LA, Dessources K, Abu-Rustum NR, Aghajanian C, Tew WP, Beumer J, Sonoda Y, O'Cearbhaill RE. "Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer." J Clin Oncol. 2021.
9. Tolaney SM, Wardley AM, Zambelli S, Hilton JF, Troso-Sandoval TA, Ricci F, Im SA, Kim SB, Johnston SRD, Chan A, Goel S, Catron K, Chapman SC, Price GL, Yang Z, Gainford MC, André F. "Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with HR+, HER2+ advanced breast cancer." Lancet Oncol. 2020.
10. Rubinstein MM, Hyman DM, Caird I, Won H, Soldan K, Seier K, Iasonos A, Tew WP, O'Cearbhaill RE, Grisham RN, Hensley ML, Troso-Sandoval T, Sabbatini P, Guillen J, Selcuklu SD, Zime I, Torrisi J, Aghajanian C, Makker V. "Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway." Cancer. 2020.
11. Iyengar NM, Smyth L, Lake D, Gucalp A, Singh JC, Traina TA, DeFusco P, Dickler MN, Fornier MN, Goldfarb SB, Jhaveri K, Modi S, Troso-Sandoval T, Patil S, Ulaner G, Jochelson M, Norton L, Hudis CA, Dang CT. "Efficacy and Safety of Gemcitabine with Trastuzumab and Pertuzumab after Prior Pertuzumab-based Therapy in Patients with Human Epidermal Growth Factor Receptor-2 Positive Metastatic Breast Cancer." JAMA Network Open. 2019.

12. Soumerai TE, Donoghue MTA, Bandlamudi C, Srinivasan P, Chang MT, Zamarin D, Cadoo KA, Grisham RN, O'Cearbhaill RE, Tew WP, Konner JA, Hensley ML, Makker V, Sabbatini P, Spriggs DR, Troso-Sandoval TA, Charen AS, Friedman C, Gorsky M, Schweber SJ, Middha S, Murali R, Chiang S, Park KJ, Soslow RA, Ladanyi M, Li BT, Mueller J, Weigelt B, Zehir A, Berger MF, Abu-Rustum NR, Aghajanian C, DeLair DF, Solit DB, Taylor BS, Hyman DM. "Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer." Clin Cancer Res. 2018.
13. Iyengar NM, Fornier MN, Sugarman S, Theodoulou M, Troso-Sandoval TA, D'Andrea G, Drullinsky P, Fasano J, Gajria D, Goldfarb SB, Comen EA, Lake D, Modi S, Traina TA, Chen M, Patil S, Baselga J, Norton L, Hudis CA, Dang CT. "A Pilot Study of Dose-Dense Paclitaxel with Trastuzimab and Lapatinib for node-negative, HER-2 Overexpressed Breast Cancer." Clin Breast Cancer. 2016.
14. Drullinsky P, Troso-Sandoval T, Seidman AD, Yuan J, Patel H, Patil S, Norton L, Hudis C. "Dose Dense Adjuvant Cyclophosphamide, Methotrexate, Fluorouracil is feasible at 14 Day Intervals." Clin Breast Cancer. 2010.
15. Dang C, D'Andrea G, Lake D, Sugarman S, Fornier M, Moynahan ME, Gilewski T, Hurria A, Mills N, Troso-Sandoval T, George R, Robson M, Dickler M, Smith K, Panageas KS, Norton L, Hudis CA. "Prolonged dose dense epirubicin and cyclophosphamide followed by paclitaxel in breast cancer is feasible." Clin Breast Cancer. 2008.
16. Sugarman S, Wasserheit C, Hodgeman E, Coglianese M, D'Alassandro A, Fornier M, Troso-Sandoval T, D'Andrea G, Drullinsky P, Lake D, George R, Mills N, Moynahan M, Smith J, Panageas K, Norton L, Hudis C. "A pilot study of dose dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma." Breast Cancer Res Treat. 2008.
17. Dang C, Fornier M, Sugarman S, Troso-Sandoval T, Lake D, D'Andrea G, Seidman A, Sklarin N, Dickler M, Currie V, Gilewski T, Moynahan ME, Drullinsky P, Robson M, Wasserheit-Leiblich C, Mills N, Steingart R, Panageas K, Norton L, Hudis C. "The safety of dose dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer." J Clin Oncol. 2008.
18. Deng G, Vickers A, Yeung S, D'Andrea GM, Xiao H, Heerdt AS, Sugarman S, Troso-Sandoval T, Seidman AD, Hudis CA, Cassileth B. "Randomized, controlled trial of acupuncture for the treatment of hot flashes in breast cancer." J Clin Oncol. 2007.
19. Munster P, Troso-Sandoval T, Rosen N, Rifkind R, Marks P, Richon V. "The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Induces Differentiation of Human Breast Cancer Cells." Clin Cancer Res. 2001.
20. Xie Q-W, Cho H, Calaycay J, Mumford R, Swiderek K, Lee T, Ding A, Troso T, Nathan C. "Cloning and Characterization of Inducible Nitric Oxide Synthase from Mouse Macrophages." Science. 1992.

Reviews

1. Troso-Sandoval TA, Lichtman SM. "Chemotherapy of Ovarian Cancer in Elderly Patients." Cancer Biol Med. 2015.